



From microbes to One Health



Expert in infectious diseases solutions

From Microbes to One Health

www.vibiosphen.com

Vibiosphen's Team



Maxime FONTANIÉ, MBA
CEO



Patricia MARTIN, PhD
CSO



Christophe FREMEZ, MSc
Head of Laboratory



Alexandre LAURENT, MSc
Pharmacologue



Robin Dumas, MSc
Business Development



Célia LECACHEUX, MSc
Pharmacologue

Vibiosphen's Overview



- ❖ Services
 - *in vitro*
 - *in vivo*



- ❖ Organoids
- ❖ Pharmamicrobiotics




- ❖ Polypeptidoids

CRO – **PRO** – R&D

Vibiosphen combines expertise, network and knowledges in drug discovery, drug development and pharmacology in *infectious diseases area*

One Health vision




- ❖ Limitation of exposure
- ❖ Decrease of antibiotic misuse
- ❖ Control of pharmaceutical release
- ❖ Adopting a multidisciplinary approach

One health is about controlling the likelihood of getting in contact with diseases and developing modern treatment with a *systemic approach*.

Pharmamicrobiotics

Drugs impact on
gut microbiota



Gut microbiota
impact on drugs

❖ *In vitro* model

Human microbiota in process


❖ *In vivo* model

Pathological microbiota in process




Pharmamicrobiotics aims to bring to the preclinical services a new set of tools in order to *gain time and spare resources in drug development.*


Overview Vibiosphen's offer



ESKAPE



Sars-Cov-2 | influenza | RSV



Aspergillus | Candida

Microbiology and animal facilities (biosafety level 2 & biosafety level 3)

In vitro services

MIC

MBC

TKC

Antibiogram

Overview Vibiosphen's offer

In vivo services



Balb-c | Swiss | other mice genetic background

In house models

Gastro intestinal

Septicemia

Urinary tract

Pulmonary

Skin

Thigh

Custom

Route of administration

- ❖ Intravenous
- ❖ *Per os*
- ❖ Sub cutaneous
- ❖ Intra nasal
- ❖ Intra peritoneal
- ❖ Inhalation

End points

- ❖ Clinical score
- ❖ Body weight
- ❖ Survival
- ❖ Bacterial - viral and fungal load
- ❖ Cytokine / chemokine
- ❖ Immune cell quantification
- ❖ Histopathological analysis



VIBIOSPHEN

From microbes to One Health

www.vibiosphen.com

Robin DUMAS, Business Developer
Mobile : +337 82 72 76 23
robin.dumas@vibiosphen.com

Patricia Martin, CSO
Mobile : +336 41 90 79 89
patricia.martin@vibiosphen.com

Maxime FONTANIÉ, CEO
Mobile : +336 50 15 53 97
maxime.fontanie@vibiosphen.com

